[go: up one dir, main page]

KR870011129A - 디스타마이신 a 동족체 및 이의 제조방법 - Google Patents

디스타마이신 a 동족체 및 이의 제조방법 Download PDF

Info

Publication number
KR870011129A
KR870011129A KR870004929A KR870004929A KR870011129A KR 870011129 A KR870011129 A KR 870011129A KR 870004929 A KR870004929 A KR 870004929A KR 870004929 A KR870004929 A KR 870004929A KR 870011129 A KR870011129 A KR 870011129A
Authority
KR
South Korea
Prior art keywords
carboxamido
pyrrole
methyl
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR870004929A
Other languages
English (en)
Other versions
KR950011408B1 (ko
Inventor
라자리 에토레
아르카모네 페데리코
펜코 세르지오
안토니에타 베리니 마리아
몬겔리 니콜라
Original Assignee
비토리노 페라리오
팜이탈리아 카를로 엘바 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비토리노 페라리오, 팜이탈리아 카를로 엘바 에스.피.에이. filed Critical 비토리노 페라리오
Publication of KR870011129A publication Critical patent/KR870011129A/ko
Application granted granted Critical
Publication of KR950011408B1 publication Critical patent/KR950011408B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

디스타마이신 A 동족체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 염.
    상기 식에서,
    n은 2,3 또는 4이고;
    및 Het-(여기서, Het는 피롤을 제외한 5원 또는 6원 헤테로모노사이클릭 환이다)으로부터 선택한 2가 라디칼이며, 이 라디칼은 C1-C6알킬, C1-C6알콕시, 시아노 및 트리플루오로메틸로부터 선택한 하나 이상의 치환제로 치환되거나 비치환되며;
    R1및 R2중의 하나는 수소이고, 다른 하나는 a)그룹(여기서, R3는 할로겐원자로 치환되거나 비치환된 C1-C6알킬; 페닐; 또는 사이클로헥실이다)또는 b) 그룹-CO-(CH2)m-R4(여기서, m은 0,1,2 또는 3이고, R4는 수소, 할로겐, 하이드록시, 아지리디닐 또는 옥시라닐이다)이거나, R1및 R2는 동일하고, 둘다 수소, 또는 할로겐, 하이드록시 또는 C1-C6알콕시로 치환되거나 비치환된 C1-C6알킬그룹이다.
  2. 제 1 항에 있어서, n이 3이고 ; A가및 그룹-Het-〔여기서, -Het-는 산소, 황 및 질소로부터 선택한 1개 또는 2개의 헤테로원자를 함유하고 C1-C6알킬로 치환되거나 비치환된 5원 또는 6원 헤테로모노사이클릭 환(단, 피롤은 제외)이다〕으로부터 선택한 2가 라디칼이며;그룹는 (i)(여기서, R3는 비치환되거나, 할로-치환된 C1-C6알킬이다) 또는(ii)〔여기서 R1′및 R2′는 동일하고, 각각 할로-치환된 C1-C6알킬이다)〕인 일반식 (Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 염.
  3. 제 2 항에 있어서, 5원 또는 6원 헤테로모노 사이클릭 환이 티오펜, 티아졸, 피리딘, 이소옥사졸, 푸란. 트리아졸, 이미다졸 또는 1-메틸-이미다졸인 화합물.
  4. 염산염 형태의,
    β-〔1-메틸-4-〔1-메틸-4-〔1-메틸-4-〔4-(N′-메틸-N′-니트로소우레이도벤젠)-1-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕프로피온아미딘;
    β-〔1-메틸-4-〔1-메틸-4-〔1-메틸-4-〔4-(N′-(2-클로로에틸)-N′-니트로소우레이도벤젠)-1-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕프로피온아미딘;
    β-〔1-메틸-4-〔1-메틸-4-〔1-메틸-4-〔4-N,N-비스(2-클로로에틸)아미노티오펜-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕프로피온아미딘;
    β-〔1-메틸-4-〔1-메틸-4-〔1-메틸-4-〔4-N,N-비스(2-클로로에틸)아미노벤젠-1-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕프로피온아미딘, 및 β-〔1-메틸-4-〔1-메틸-4-〔1-메틸-4-〔3-N,N-비스(2-클로로에틸)아미노벤젠-1-카복스아미도〕피헤-2-카복스아미도〕피롤-2-카복스아미도〕피롤-2-카복스아미도〕프로피온아미딘으로 이루어진 그룹 중에서 선택한 화합물.
  5. 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물과 반응시키고, 경우에 따라 일반식(Ⅰ)의 화합물을 염화하거나 염으로부터 유리 화합물을 수득하고/하거나, 경우에 따라, 일반식(Ⅰ)의 이성체 혼합물을 단일이성체로 분리시킴을 특징으로 하여 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염을 제조하는 방법.
    상기 식에서,
    n은 2,3 또는 4이고 ;
    A는
    및 Het-(여기서, Het는 피롤을 제외한 5원 또는 6원 헤테로모노사이클릭 환이다)으로부터 선택한 2가 라디칼이며, 이 라디칼은 C1-C6알킬, C1-C6알콕시, 시아노 및 트리플루오로메틸로부터 선택한 하나 이상의 치환제로 치환되거나 비치환되고 ;
    R1및 R2중의 하나는 수소이고, 다른 하나는 a) 그룹(여기서, R3는 할로겐원자로 치환되거나 비치환된 C1-C6알킬;페닐;또는 사이클로헥실이다)또는 b) 그룹--CO-(CH2)m-R4(여기서, m은 0,1,2 또는 3이고, R4는 수소, 할로겐, 하이드록시, 아지리디닐 또는 옥시라닐이다)이거나, R1및 R2는 동일하고, 둘다 수소, 또는 할로겐, 하이드록시 또는 C1-C6알콕시로 치환되거나 비치환된 C1-C6알킬그룹이며 ;
    X 는 하이드록시 또는 이탈그룹이다.
  6. 활성 성분으로서 제 1 항에 따르는 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이의 염과 , 약제학적으로 허용되는 담체 및/ 또는 희석제를 합유하는 약제학적 조성물.
  7. 항종양제 및 항바이러스제로서 사용하기 위한 제 1 항에 따르는 일반식(Ⅰ)의 화합물.
  8. 항종양제 및 항바이러스제로서 사용하기 위한 제 6 항에 따르는 약제학적 조성물.
  9. 항종양제 및 항바이러스제로서의 활성을 갖는 제 6 항에 따르는 약제학적 조성물을 제조하기 위한 제 1 항에 따르는 일반식(Ⅰ)의 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870004929A 1986-05-20 1987-05-19 디스타마이신 a 동족체의 제조방법 Expired - Fee Related KR950011408B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868612218A GB8612218D0 (en) 1986-05-20 1986-05-20 Site specific alkylating agents
GB8612218 1986-05-20

Publications (2)

Publication Number Publication Date
KR870011129A true KR870011129A (ko) 1987-12-21
KR950011408B1 KR950011408B1 (ko) 1995-10-04

Family

ID=10598117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870004929A Expired - Fee Related KR950011408B1 (ko) 1986-05-20 1987-05-19 디스타마이신 a 동족체의 제조방법

Country Status (27)

Country Link
US (1) US5017599A (ko)
EP (1) EP0246868B1 (ko)
JP (1) JPH0623193B2 (ko)
KR (1) KR950011408B1 (ko)
AT (1) ATE80617T1 (ko)
AU (1) AU597659B2 (ko)
BG (1) BG60531B2 (ko)
BR (1) BR1101017A (ko)
CA (1) CA1314551C (ko)
CS (1) CS413791A3 (ko)
DE (1) DE3781716T2 (ko)
DK (1) DK254587A (ko)
ES (1) ES2046202T3 (ko)
FI (1) FI86543C (ko)
GB (1) GB8612218D0 (ko)
GR (1) GR3006163T3 (ko)
HK (1) HK31993A (ko)
HU (1) HU201336B (ko)
IE (1) IE60198B1 (ko)
IL (1) IL82553A (ko)
MX (1) MX9203122A (ko)
NZ (1) NZ220361A (ko)
PT (1) PT84896B (ko)
SG (1) SG3793G (ko)
SU (1) SU1528316A3 (ko)
UA (1) UA5928A1 (ko)
ZA (1) ZA873593B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN85103908A (zh) * 1985-07-16 1986-11-05 法米塔利·卡洛·埃尔巴有限公司 制备4′-表多克索红菌素的新方法
GB8906709D0 (en) * 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives
IT1262921B (it) * 1992-01-10 1996-07-22 Federico Arcamone Agenti antitumorali analoghi di oligopeptidi pirrol-amidinici retroversi processi di preparazione e prodotti farmaceutici che li contengono
IT1271456B (it) * 1993-03-01 1997-05-28 Menarini Farma Ind Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
GB9416005D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
EP0750913A3 (en) * 1995-06-30 1997-11-05 Takeda Chemical Industries, Ltd. Disaccharide containing freeze-dried preparation for pharmaceutical use
GB9514993D0 (en) * 1995-07-21 1995-09-20 Pharmacia Spa Site specific phenyl nitrogen mustards
US5808087A (en) 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
JP2000503999A (ja) * 1996-02-02 2000-04-04 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー ジスタマイシン誘導体、その調製方法、および抗腫瘍および抗ウイルス剤としてのその使用
US6090947A (en) * 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
US6506906B1 (en) 1996-02-26 2003-01-14 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
US6555692B1 (en) 1996-02-26 2003-04-29 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
EP0968186A1 (en) 1996-02-26 2000-01-05 California Institute Of Technology Improved polyamides for binding in the minor groove of double stranded dna
US6635417B1 (en) 1996-07-31 2003-10-21 California Institute Of Technology Complex formation between DSDNA and oligomer of cyclic heterocycles
AU6757698A (en) 1996-02-26 1998-10-30 California Institute Of Technology Stereochemical control of the dna binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove
GB9610079D0 (en) * 1996-05-14 1996-07-17 Pharmacia Spa Distamycin deriratives process for preparing them and their use as antitumor and antiviral agents
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
US5998140A (en) * 1996-07-31 1999-12-07 The Scripps Research Institute Complex formation between dsDNA and oligomer of cyclic heterocycles
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
GB9816652D0 (en) * 1998-07-30 1998-09-30 Pharmacia & Upjohn Spa Sulfurated distamycin derivatives process for preparing them and their use as antitumor agents
GB9816653D0 (en) * 1998-07-30 1998-09-30 Pharmacia & Upjohn Spa Oxidised sulfurated distamycin derivatives process for preparing them and their use as antitumor agents
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US6559125B1 (en) 2000-01-28 2003-05-06 California Institute Of Technology Polyamide-alkylator conjugates and related products and method
US7078536B2 (en) * 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
JP2003529609A (ja) 2000-03-16 2003-10-07 ジーンソフト インコーポレイティッド 核酸結合部分を含む荷電した化合物およびその利用法
GB0011059D0 (en) 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015447D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015446D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
GB0016447D0 (en) 2000-07-04 2000-08-23 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
GB0029004D0 (en) 2000-11-28 2001-01-10 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
WO2002088119A1 (en) * 2001-04-26 2002-11-07 Genesoft Pharmaceuticals, Inc Halogen-substituted thienyl compounds
US6969592B2 (en) 2001-09-26 2005-11-29 Pharmacia Italia S.P.A. Method for predicting the sensitivity to chemotherapy
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
WO2004039318A2 (en) * 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
EP1587529A4 (en) 2002-12-10 2009-08-12 Oscient Pharmaceuticals Corp ANTIBACTERIAL COMPOUNDS WITH (PYROCARBOXAMIDE) - (BENZAMID) - (IMIDAZOLE CARBOXAMIDE) MOTIVE
GB202114032D0 (en) * 2021-09-30 2021-11-17 Univ Strathclyde Antivirals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR86210E (ko) * 1963-04-04 1966-03-23
FR141F (ko) * 1963-07-26
BR6461040D0 (pt) * 1963-07-26 1973-08-02 Farmaceutici Italia Processo para preparar novos derivados de pirrol
DE1795539A1 (de) * 1963-07-26 1972-01-13 Farmaceutici Italia Verfahren zur Herstellung von neuen Pyrrolderivaten und ihren Salzen
NL130086C (ko) * 1964-07-14 1970-06-15
CN85103908A (zh) * 1985-07-16 1986-11-05 法米塔利·卡洛·埃尔巴有限公司 制备4′-表多克索红菌素的新方法
GB8517922D0 (en) * 1985-07-16 1985-08-21 Erba Farmitalia Carboxamido derivatives

Also Published As

Publication number Publication date
EP0246868B1 (en) 1992-09-16
US5017599A (en) 1991-05-21
SU1528316A3 (ru) 1989-12-07
DE3781716T2 (de) 1993-03-11
IL82553A (en) 1991-06-10
NZ220361A (en) 1990-04-26
HUT44044A (en) 1988-01-28
FI872173A0 (fi) 1987-05-18
JPH0623193B2 (ja) 1994-03-30
PT84896B (pt) 1990-02-08
AU597659B2 (en) 1990-06-07
ATE80617T1 (de) 1992-10-15
CA1314551C (en) 1993-03-16
IE60198B1 (en) 1994-06-15
CS413791A3 (en) 1992-09-16
DK254587D0 (da) 1987-05-19
UA5928A1 (uk) 1994-12-29
PT84896A (en) 1987-06-01
BR1101017A (pt) 1999-12-07
MX9203122A (es) 1992-07-01
IE871292L (en) 1987-11-20
HU201336B (en) 1990-10-28
IL82553A0 (en) 1987-11-30
FI86543B (fi) 1992-05-29
FI86543C (fi) 1992-09-10
ES2046202T3 (es) 1994-02-01
GR3006163T3 (ko) 1993-06-21
FI872173L (fi) 1987-11-21
DE3781716D1 (de) 1992-10-22
DK254587A (da) 1987-11-21
JPS62294653A (ja) 1987-12-22
EP0246868A1 (en) 1987-11-25
BG60531B2 (bg) 1995-07-28
SG3793G (en) 1993-03-12
ZA873593B (en) 1987-11-12
KR950011408B1 (ko) 1995-10-04
GB8612218D0 (en) 1986-06-25
HK31993A (en) 1993-04-08
AU7316387A (en) 1987-11-26

Similar Documents

Publication Publication Date Title
KR870011129A (ko) 디스타마이신 a 동족체 및 이의 제조방법
KR900018098A (ko) 피리돈 카르복실산과 항균제
KR950005827A (ko) 신규 2- 아미노티아졸카르복사미드 유도체, 그의 제조방법 및 식물병원균 퇴치를 위한 그의 용도
KR920021523A (ko) 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물
IE41539L (en) Chroman derivatives.
YU47099B (sh) Postupak za dobijanje makrolidnih jedinjenja
KR870006016A (ko) N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
KR840007412A (ko) 벤조-헤테로 고리 화합물의 제조방법
KR900016220A (ko) 매크로리드 조성물
KR830000694A (ko) 헤테로싸이클 유도체의 제조방법
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR850003719A (ko) 시아노피라졸 제초제에 대한 개량
KR900014396A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR890016017A (ko) 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드
KR840001177A (ko) 제초제인 설폰아미드의 제조방법
KR870001203A (ko) 치환된 3-아미노-시드논이민의 제조 방법
KR910004559A (ko) 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체
SE8008555L (sv) Tioetylamidderivat
KR840007406A (ko) 중추 신경계에 활성을 나타내는 복소환 화합물의 제조방법
KR840005118A (ko) 헤테로사이클릭 아민의 제조방법
KR840008323A (ko) 5-아실-2-(1h)-피리디논의 제조방법
KR900018042A (ko) 부텐산 유도체
KR880002889A (ko) 일차 복조환식아민의 디세레노비스 벤조산아민과 그 제조방법 및 약제화합물
KR910000133A (ko) 아민

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20000928

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20011005

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20011005